High-Density Lipoprotein and Cardiovascular Disease—Where do We Stand?
Authors:
- 4 July 2022
- journal article
- research article
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 51 (3) , 557-572
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Inflammation modulates human HDL composition and function in vivoAtherosclerosis, 2012
- On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin TherapyJACC, 2012
- LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 IndividualsThe Journal of Clinical Endocrinology & Metabolism, 2012
- Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesisJournal of Lipid Research, 2011
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglyceridesNature, 2011
- Genetic causes of high and low serum HDL-cholesterolJournal of Lipid Research, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Lipid rafts and B cell signalingSeminars in Cell & Developmental Biology, 2007
- Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLJournal of Clinical Investigation, 2007